Lorlatinib
Third generation ALK/ROS1 inhibitor
An ALK/ROS1 inhibitor designed to cross the blood-brain barrier and address some resistance mutations.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
- Generic name
- lorlatinib
- Marketed brand names
- Lorbrena
- Route
- Orally
- Drug class
- Third generation ALK/ROS1 inhibitor
Registration status
Registration status and availability in Indonesia must be confirmed directly with the health facility or authorized distributor. This page is not a source of marketing approval status.
Not a marketing-authorisation source
TanyaKanker does not state a drug's marketing approval status in Indonesia. Confirm official status only through a healthcare facility, BPOM, or an authorised distributor.
Access considerations
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
What needs verification
- Indications approved in the country where the drug is used.
- Compliance with the patient's latest biological marker examination results.
- Plan to monitor side effects and interactions with other drugs being used.
Related
Sources
- NCI Drug Dictionary(lembaga)
Studies related to this drug marker
NCT01639508Phase 2Combination regimen
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Lung Cancer | biomarker: ROS1, MET, RET, NTRK
United States7 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker ROS1.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT01639508Not verified
NCT06315010Phase 2Targeted therapy
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
Lung Cancer | biomarker: ROS1 | Targeted therapy
Austria, Germany, Spain17 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker ROS1, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06315010Not verified
Request cost and access questions
We prepare cost and availability questions that need direct confirmation from a facility.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- ALK
Biomarker
Reason: Targets this marker
- ROS1
Biomarker
Reason: Targets this marker
- Targeted therapy
Treatment category
Reason: Uses this drug
- Lung cancer with spread to the brain
Decision situation
Reason: Related to this page
- Lung cancer progression after targeted therapy
Decision situation
Reason: Related to this page
- ALK fusion (EML4-ALK)
Molecular alteration
Reason: Related to this page
To check
- Cost and access questions
Tool
Reason: Prepare questions to ask a facility
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.